CJC-1295 with DAC

CJC-1295 with DAC, also published as DAC:GRF, is catalogued here as: GHRH analogue with Drug Affinity Complex. The long-acting CJC-1295 molecule was studied in healthy adults for growth-hormone and IGF-I responses. A long-acting peptide studied in clinical experiments for changes in growth hormone and IGF-I, a growth-related marker.

Human trial literature: Two randomized studies lasting 28 and 49 days reported sustained increases in GH and IGF-I after the long-acting CJC-1295 intervention. These are hormone biomarkers, not performance or anti-ageing outcomes.

Human trial literature: No serious adverse reactions were reported in these short studies. This does not establish long-term safety; long-acting data must not be transferred to non-DAC material or blends.

When comparing published work, match the exact molecular identity, salt form and strength to the paper. Findings in cell or animal models describe those models only and do not establish outcomes in people. The reconstitution calculator converts vial content and diluent volume into concentration for laboratory preparation.

Proof Line Peptides lists CJC-1295 with DAC as a vial in 5 mg, with pack sizes of 1, 3, 5 and 10. Prices are shown in Canadian dollars, and orders ship from Toronto by tracked Canadian service.

A lab report for CJC-1295 with DAC is available on request. Proof Line Peptides does not display a report until it is matched to the exact compound and strength.

Shipped lyophilized (freeze-dried) and stable at room temperature in transit. Store sealed vials in the fridge or freezer on arrival. Once reconstituted, refrigerate. Anything not right? Our guarantee covers it.